ISPE Announces 2013-2014 Board of Directors Election Results

ISPE Announces 2013-2014 Board of Directors Election Results
PR Newswire
TAMPA, Fla., Oct. 14, 2013
TAMPA, Fla., Oct. 14, 2013 /PRNewswire-USNewswire/ --ISPE has announced the
results of its 2013-2014 International Board of Directors election, revealing
a slate of strategic leaders who represent a variety of pharmaceutical
industry sectors. The Board will be responsible for the governance and
strategic direction of the Society and will assume their elected positions at
the 2013 ISPE Annual Meeting, 3 – 6 November in Washington, DC USA.
(Logo: http://photos.prnewswire.com/prnh/20120912/DC73253LOGO)
"ISPE is in the midst of significant growth and transitioning to guide and
support the pharmaceutical industry as it addresses issues such as increasing
regulatory and pricing pressures, global markets, supply chains and
manufacturing innovation," said ISPE President and CEO Nancy Berg. "I am
confident that the incoming International Board of Directors will build upon
the work of previous Boards and the Society's past success and lead ISPE in
its mission to support the pharmaceutical industry's efforts to provide safe,
high quality medications for patients around the world."
The following pharmaceutical industry leaders have been elected to positions
on the 2013-2014 ISPE International Board of Directors:
Officers:
oChair: Damian Greene, Global Network Strategy Lead, Global Manufacturing
and Supply, Zoetis
oVice Chair: Andy Skibo, Regional Vice President, Biologics-Supply,
MedImmune/AstraZeneca
oTreasurer: Joseph Famulare, Vice President – Global Compliance and
External Collaboration, Genentech
oSecretary: Mike Arnold, RPh, Business Process Owner for Investigational
Products and Senior Director of Strategic Partnerships, Global Clinical
Supply Chain, Pfizer
oPast Chair: Charlotte Enghave Fruergaard, PhD, Partner, Global Consulting,
NNE Pharmaplan
Re-elected Directors:
oJames A. Breen, Jr., PE, LEED AP, Vice President, Worldwide Engineering
and Technical Operations, Supply Chain Group, Johnson & Johnson
oTim Howard, CPIP, PE, Vice President of Global Operations and Company
Officer, Commissioning Agents, Inc.
New Directors:
oMark Fitch, Senior Vice President of Global Operations, Impax
Laboratories, Inc.
oThomas Hartman, Vice President, GMP Operations, Biopharm CMC, GlaxoSmith
Kline
oRobert "Bob" Matje, PE, CPIP, Senior Director of Engineering, Endo
oChristopher "Chris" Reid, CEO and Principal Consultant and Owner,
Integrity Solutions Ltd.
oFran Zipp (Sakers), Group Executive Vice President and Head of Quality
Operations, Teva
In addition to those named above, Directors Jennifer Lauria Clark, CPIP, Jim
Durkin, and Gordon Leichter, PhD, each of whom were elected in 2012 to serve a
two-year term, will continue their service on the Board. Complete biographical
information on all of ISPE's Directors can be found at the ISPE Board of
Directors webpage.
About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the world's
largest not-for-profit association serving its Members through leading
scientific, technical and regulatory advancement throughout the entire
pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in
the development and manufacture of safe and effective pharmaceutical and
biologic medicines and medical delivery devices in more than 90 countries
around the world. Founded in 1980, ISPE has its worldwide headquarters in
Tampa, Florida, USA and offices in Brussels, Belgium, Singapore and Shanghai,
China. Visit www.ISPE.org for more information.
For more information contact:
Danielle Hould
ISPE Membership Marketing Communications Manager
Tel: +1-813-960-2105, ext. 277
email: dhould@ispe.org
www.ISPE.org
SOURCE ISPE
Website: http://www.ispe.org